Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Notches First Sales of Aura Skin Cancer Detection Device

Premium

Verisante Technology said this week that it has received the first orders for its Raman spectroscopy-based Aura skin cancer detection system and plans an initial production run of 10 devices to be placed in Canada and Europe.

The company will begin shipping the devices this month to its Canadian distributor Clarion and Laserwelt, its distributor for Germany, Austria, and Liechtenstein.

Sales of the device were originally slated to launch in the middle of 2012. This launch was delayed, however, by improvements to the device that necessitated additional beta testing as well as recently added electrical safety testing rules in Europe, Verisante CEO Thomas Braun told ProteoMonitor in a November interview (PM 11/30/2012).

The Aura uses Raman spectroscopy to measure the levels of various biomarkers – including proteins, nucleic acids, and metabolites – in skin lesions to distinguish between benign and malignant lesions. By comparing the patterns of spectra generated by the device, clinicians can differentiate between the two.

The sales clear the way for Verisante to move toward US Food and Drug Administration approval for the device, which the company has delayed pursuing pending its commercial launch.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.